{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:21:13Z","timestamp":1794576073071,"version":"4.9.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/T028084\/1"],"award-info":[{"award-number":["MR\/T028084\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We investigated the potential role of the opioid system in modulating glutamatergic effects of ketamine administration in major depressive disorder. Twenty-six adults with major depressive disorder participated in a double-blind crossover study, receiving oral placebo or 50\u2009mg naltrexone before an intravenous infusion of 0.5\u2009mg per kg ketamine. Brain glutamatergic activity in the anterior cingulate cortex was measured using functional magnetic resonance spectroscopy and depressive symptoms were assessed with the Montgomery\u2013\u00c5sberg Depression Rating Scale. Naltrexone attenuated the increase in glutamate\u2009+\u2009glutamine to total\n                    <jats:italic>N<\/jats:italic>\n                    -acetylaspartate ratio during ketamine infusion compared to placebo (\n                    <jats:italic>F<\/jats:italic>\n                    <jats:sub>1,253<\/jats:sub>\n                    \u2009=\u20094.83,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.029) and also attenuated the reduction in Montgomery\u2013\u00c5sberg Depression Rating Scale scores on day 1 (condition-by-time interaction,\n                    <jats:italic>F<\/jats:italic>\n                    <jats:sub>1,74\u2009<\/jats:sub>\n                    =\u20095.39,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.023). These findings demonstrate that the opioid system modulates the acute response to ketamine and subsequent antidepressant effects. Interactions between the glutamate and opioid systems may have implications for the development of new depression treatment strategies. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04977674\" ext-link-type=\"uri\">NCT04977674<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-03800-w","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T09:02:45Z","timestamp":1753347765000},"page":"2958-2966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6398-5239","authenticated-orcid":false,"given":"Luke A.","family":"Jelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5078-9025","authenticated-orcid":false,"given":"David J.","family":"Lythgoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3051-0135","authenticated-orcid":false,"given":"James M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-6952","authenticated-orcid":false,"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1152-5323","authenticated-orcid":false,"given":"Mitul A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"3800_CR1","doi-asserted-by":"crossref","unstructured":"Jelen L. A. & Stone J. M. Ketamine for depression. Int. Rev. Psychiatry 33, 207\u2013228 (2021).","DOI":"10.1080\/09540261.2020.1854194"},{"key":"3800_CR2","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","volume":"277","author":"WS Marcantoni","year":"2020","unstructured":"Marcantoni, W. S. et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009\u2013January 2019. J. Affect Disord. 277, 831\u2013841 (2020).","journal-title":"J. Affect Disord."},{"key":"3800_CR3","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","volume":"101","author":"JH Krystal","year":"2019","unstructured":"Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S. & Duman, R. S. Ketamine: a paradigm shift for depression research and treatment. Neuron 101, 774\u2013778 (2019).","journal-title":"Neuron"},{"key":"3800_CR4","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.biopsych.2016.05.005","volume":"81","author":"MS Lener","year":"2017","unstructured":"Lener, M. S. et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol. Psychiatry 81, 886\u2013897 (2017).","journal-title":"Biol. Psychiatry"},{"key":"3800_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/mp.2016.34","volume":"22","author":"GMI Chowdhury","year":"2017","unstructured":"Chowdhury, G. M. I. et al. Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Mol. Psychiatry 22, 120\u2013126 (2017).","journal-title":"Mol. Psychiatry"},{"key":"3800_CR6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.biopsych.2011.11.006","volume":"71","author":"GMI Chowdhury","year":"2012","unstructured":"Chowdhury, G. M. I. et al. 1H-[13C]-nuclear magnetic resonance spectroscopy measures of ketamine\u2019s effect on amino acid neurotransmitter metabolism. Biol. Psychiatry 71, 1022\u20131025 (2012).","journal-title":"Biol. Psychiatry"},{"key":"3800_CR7","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","volume":"17","author":"B Moghaddam","year":"1997","unstructured":"Moghaddam, B., Adams, B., Verma, A. & Daly, D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921\u20132927 (1997).","journal-title":"J. Neurosci."},{"key":"3800_CR8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/mp.2011.171","volume":"17","author":"JM Stone","year":"2012","unstructured":"Stone, J. M. et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol. Psychiatry 17, 664\u2013665 (2012).","journal-title":"Mol. Psychiatry"},{"key":"3800_CR9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1176\/appi.ajp.162.2.394","volume":"162","author":"LM Rowland","year":"2005","unstructured":"Rowland, L. M. et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am. J. Psychiatry 162, 394\u2013396 (2005).","journal-title":"Am. J. Psychiatry"},{"key":"3800_CR10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1001\/jamapsychiatry.2017.3572","volume":"75","author":"DC Javitt","year":"2018","unstructured":"Javitt, D. C. et al. Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial. JAMA Psychiatry 75, 11\u201319 (2018).","journal-title":"JAMA Psychiatry"},{"key":"3800_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/mp.2015.83","volume":"21","author":"MS Milak","year":"2016","unstructured":"Milak, M. S. et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol. Psychiatry 21, 320\u2013327 (2016).","journal-title":"Mol. Psychiatry"},{"key":"3800_CR12","doi-asserted-by":"crossref","first-page":"e2013211","DOI":"10.1001\/jamanetworkopen.2020.13211","volume":"3","author":"MS Milak","year":"2020","unstructured":"Milak, M. S. et al. Assessment of relationship of ketamine dose with magnetic resonance spectroscopy of Glx and GABA responses in adults with major depression: a randomized clinical trial. JAMA Netw. Open. 3, e2013211 (2020).","journal-title":"JAMA Netw. Open."},{"key":"3800_CR13","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/s41386-018-0136-3","volume":"43","author":"CG Abdallah","year":"2018","unstructured":"Abdallah, C. G. et al. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology 43, 2154\u20132160 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"3800_CR14","doi-asserted-by":"crossref","unstructured":"Evans, J. W. et al. 7T 1H-MRS in major depressive disorder: a ketamine treatment study. Neuropsychopharmacology 43, 1908\u20131914 (2018).","DOI":"10.1038\/s41386-018-0057-1"},{"key":"3800_CR15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0269881120959644","volume":"35","author":"LA Jelen","year":"2021","unstructured":"Jelen, L. A., Young, A. H. & Stone, J. M. Ketamine: a tale of two enantiomers. J. Psychopharmacol. 35, 109\u2013123 (2021).","journal-title":"J. Psychopharmacol."},{"key":"3800_CR16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos, P. et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharm. Rev. 70, 621\u2013660 (2018).","journal-title":"Pharm. Rev."},{"key":"3800_CR17","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","volume":"117","author":"ME Klein","year":"2020","unstructured":"Klein, M. E., Chandra, J., Sheriff, S. & Malinow, R. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc. Natl Acad. Sci. USA 117, 2656\u20132662 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3800_CR18","doi-asserted-by":"crossref","unstructured":"Bonaventura, J. et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol. Psychiatry 26, 6704\u20136722 (2021).","DOI":"10.1038\/s41380-021-01093-2"},{"key":"3800_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02796-0","volume":"14","author":"C Jiang","year":"2024","unstructured":"Jiang, C., DiLeone, R. J., Pittenger, C. & Duman, R. S. The endogenous opioid system in the medial prefrontal cortex mediates ketamine\u2019s antidepressant-like actions. Transl. Psychiatry 14, 90 (2024).","journal-title":"Transl. Psychiatry"},{"key":"3800_CR20","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","volume":"24","author":"NR Williams","year":"2019","unstructured":"Williams, N. R. et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol. Psychiatry 24, 1779\u20131786 (2019).","journal-title":"Mol. Psychiatry"},{"key":"3800_CR21","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams, N. R. et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am. J. Psychiatry 175, 1205\u20131215 (2018).","journal-title":"Am. J. Psychiatry"},{"key":"3800_CR22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","volume":"76","author":"G Yoon","year":"2019","unstructured":"Yoon, G., Petrakis, I. L. & Krystal, J. H. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry 76, 337 (2019).","journal-title":"JAMA Psychiatry"},{"key":"3800_CR23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fphar.2014.00116","volume":"5","author":"EH Chartoff","year":"2014","unstructured":"Chartoff, E. H. & Connery, H. S. It\u2019s MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. Front. Pharmacol. 5, 116 (2014).","journal-title":"Front. Pharmacol."},{"key":"3800_CR24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/1874473711205030199","volume":"5","author":"J Garzon","year":"2012","unstructured":"Garzon, J., Rodriguez-Munoz, M. & Sanchez-Blazquez, P. Direct association of Mu-opioid and NMDA glutamate receptors supports their cross-regulation: molecular implications for opioid tolerance. Curr. Drug Abus. Rev. 5, 199\u2013226 (2012).","journal-title":"Curr. Drug Abus. Rev."},{"key":"3800_CR25","first-page":"269881117747579","volume":"1","author":"LA Jelen","year":"2018","unstructured":"Jelen, L. A., King, S., Mullins, P. G. & Stone, J. M. Beyond static measures: a review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia. J. Psychopharmacol. 1, 269881117747579 (2018).","journal-title":"J. Psychopharmacol."},{"key":"3800_CR26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/sjop.12411","volume":"59","author":"PG Mullins","year":"2018","unstructured":"Mullins, P. G. Towards a theory of functional magnetic resonance spectroscopy (fMRS): a meta-analysis and discussion of using MRS to measure changes in neurotransmitters in real time. Scand. J. Psychol. 59, 91\u2013103 (2018).","journal-title":"Scand. J. Psychol."},{"key":"3800_CR27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.euroneuro.2018.12.005","volume":"29","author":"LA Jelen","year":"2019","unstructured":"Jelen, L. A. et al. Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: glutamate dynamics in the anterior cingulate cortex during a working memory task. Eur. Neuropsychopharmacol. 29, 222\u2013234 (2019).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"3800_CR28","doi-asserted-by":"crossref","first-page":"15028","DOI":"10.1038\/npjschz.2015.28","volume":"1","author":"R Taylor","year":"2015","unstructured":"Taylor, R. et al. Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major depressive disorder: anterior cingulate activity during a color-word Stroop task. NPJ Schizophr. 1, 15028 (2015).","journal-title":"NPJ Schizophr."},{"key":"3800_CR29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.mri.2008.06.002","volume":"27","author":"L Chang","year":"2009","unstructured":"Chang, L., Jiang, C. S. & Ernst, T. Effects of age and sex on brain glutamate and other metabolites. Magn. Reson. Imaging 27, 142\u2013145 (2009).","journal-title":"Magn. Reson. Imaging"},{"key":"3800_CR30","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2023.103517","volume":"40","author":"DE Boucherie","year":"2023","unstructured":"Boucherie, D. E., Reneman, L., Ruh\u00e9, H. G. & Schrantee, A. Neurometabolite changes in response to antidepressant medication: a systematic review of 1H-MRS findings. Neuroimage Clin. 40, 103517 (2023).","journal-title":"Neuroimage Clin."},{"key":"3800_CR31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/nbm.2812","volume":"25","author":"A Tal","year":"2012","unstructured":"Tal, A., Kirov, I. I., Grossman, R. I. & Gonen, O. The role of gray and white matter segmentation in quantitative proton MR spectroscopic imaging. NMR Biomed. 25, 1392\u20131400 (2012).","journal-title":"NMR Biomed."},{"key":"3800_CR32","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/cercor\/bhl104","volume":"17","author":"I F\u00e9r\u00e9zou","year":"2007","unstructured":"F\u00e9r\u00e9zou, I. et al. Extensive overlap of Mu-opioid and nicotinic sensitivity in cortical interneurons. Cereb. Cortex. 17, 1948\u20131957 (2007).","journal-title":"Cereb. Cortex."},{"key":"3800_CR33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0306-4522(00)00124-X","volume":"98","author":"K Taki","year":"2000","unstructured":"Taki, K., Kaneko, T. & Mizuno, N. A group of cortical interneurons expressing mu-opioid receptor-like immunoreactivity: a double immunofluorescence study in the rat cerebral cortex. Neuroscience 98, 221\u2013231 (2000).","journal-title":"Neuroscience"},{"key":"3800_CR34","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41380-019-0480-7","volume":"26","author":"C Jiang","year":"2021","unstructured":"Jiang, C. et al. Morphine coordinates SST and PV interneurons in the prelimbic cortex to disinhibit pyramidal neurons and enhance reward. Mol. Psychiatry 26, 1178\u20131193 (2021).","journal-title":"Mol. Psychiatry"},{"key":"3800_CR35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/molpharm.124.000947","volume":"106","author":"I Gomes","year":"2024","unstructured":"Gomes, I., Gupta, A., Margolis, E. B., Fricker, L. D. & Devi, L. A. Ketamine and major ketamine metabolites function as allosteric modulators of opioid receptors. Mol. Pharmacol. 106, 240\u2013252 (2024).","journal-title":"Mol. Pharmacol."},{"key":"3800_CR36","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1176\/appi.ajp.2014.14010067","volume":"171","author":"CG Abdallah","year":"2014","unstructured":"Abdallah, C. G. et al. Glutamate metabolism in major depressive disorder. AJP 171, 1320\u20131327 (2014).","journal-title":"AJP"},{"key":"3800_CR37","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1017\/S1092852900000389","volume":"15","author":"IH Bernstein","year":"2010","unstructured":"Bernstein, I. H. et al. A comparison of the QIDS-C16, QIDS-SR16, and the MADRS in an adult outpatient clinical sample. CNS Spectr. 15, 458\u2013468 (2010).","journal-title":"CNS Spectr."},{"key":"3800_CR38","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/02698811231167848","volume":"37","author":"B Weiss","year":"2023","unstructured":"Weiss, B., Erritzoe, D., Giribaldi, B., Nutt, D. J. & Carhart-Harris, R. L. A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression. J. Psychopharmacol. 37, 717\u2013732 (2023).","journal-title":"J. Psychopharmacol."},{"key":"3800_CR39","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/mp.2017.58","volume":"23","author":"I Esterlis","year":"2018","unstructured":"Esterlis, I. et al. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. Mol. Psychiatry 23, 824\u2013832 (2018).","journal-title":"Mol. Psychiatry"},{"key":"3800_CR40","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","volume":"191","author":"GW Valentine","year":"2011","unstructured":"Valentine, G. W. et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 191, 122\u2013127 (2011).","journal-title":"Psychiatry Res."},{"key":"3800_CR41","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1176\/appi.ajp.2019.19010044","volume":"176","author":"M Wang","year":"2019","unstructured":"Wang, M. & Kaplin, A. Explaining naltrexone\u2019s interference with ketamine\u2019s antidepressant effect. AJP 176, 410\u2013411 (2019).","journal-title":"AJP"},{"key":"3800_CR42","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102493","volume":"4","author":"SM Frank","year":"2023","unstructured":"Frank, S. M. et al. Protocol to conduct functional magnetic resonance spectroscopy in different age groups of human participants. STAR Protoc. 4, 102493 (2023).","journal-title":"STAR Protoc."},{"key":"3800_CR43","first-page":"1","volume":"39","author":"CD Rae","year":"2014","unstructured":"Rae, C. D. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem. Res. 39, 1\u201336 (2014).","journal-title":"Neurochem. Res."},{"key":"3800_CR44","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/s41386-018-0027-7","volume":"43","author":"TL White","year":"2018","unstructured":"White, T. L. et al. Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans. Neuropsychopharmacology 43, 1498\u20131509 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"3800_CR45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1503\/jpn.150177","volume":"42","author":"S Njau","year":"2017","unstructured":"Njau, S. et al. Neurochemical correlates of rapid treatment response to electroconvulsive therapy in patients with major depression. J. Psychiatry Neurosci. 42, 6\u201316 (2017).","journal-title":"J. Psychiatry Neurosci."},{"key":"3800_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45157-7","volume":"15","author":"T Di Ianni","year":"2024","unstructured":"Di Ianni, T. et al. Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats. Nat. Commun. 15, 893 (2024).","journal-title":"Nat. Commun."},{"key":"3800_CR47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/jat\/bku019","volume":"38","author":"JC Liu","year":"2014","unstructured":"Liu, J. C., Ma, J. D., Morello, C. M., Atayee, R. S. & Best, B. M. Naltrexone metabolism and concomitant drug concentrations in chronic pain patients. J. Anal. Toxicol. 38, 212\u2013217 (2014).","journal-title":"J. Anal. Toxicol."},{"key":"3800_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0263-y","volume":"8","author":"M Pecina","year":"2018","unstructured":"Pecina, M., Heffernan, J., Wilson, J., Zubieta, J. K. & Dombrovski, A. Y. Prefrontal expectancy and reinforcement-driven antidepressant placebo effects. Transl. Psychiatry 8, 222 (2018).","journal-title":"Transl. Psychiatry"},{"key":"3800_CR49","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104800","volume":"140","author":"LA Jelen","year":"2022","unstructured":"Jelen, L. A., Stone, J. M., Young, A. H. & Mehta, M. A. The opioid system in depression. Neurosci. Biobehav Rev. 140, 104800 (2022).","journal-title":"Neurosci. Biobehav Rev."},{"key":"3800_CR50","doi-asserted-by":"crossref","unstructured":"Pecina, M., Chen, J., Lyew, T., Karp, J. F. & Dombrovski, A. Y. mu opioid antagonist naltrexone partially abolishes the antidepressant placebo effect and reduces orbitofrontal cortex encoding of reinforcement. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 6, 1002\u20131012 (2021).","DOI":"10.1016\/j.bpsc.2021.02.009"},{"key":"3800_CR51","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2165\/00003495-198835030-00002","volume":"35","author":"JP Gonzalez","year":"1988","unstructured":"Gonzalez, J. P. & Brogden, R. N. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35, 192\u2013213 (1988).","journal-title":"Drugs"},{"key":"3800_CR52","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan, D. V. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59, 22\u201333 (1998).","journal-title":"J. Clin. Psychiatry"},{"key":"3800_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1679-x","volume":"18","author":"A Fekadu","year":"2018","unstructured":"Fekadu, A., Donocik, J. G. & Cleare, A. J. Standardisation framework for the Maudsley staging method for treatment resistance in depression. BMC Psychiatry 18, 100 (2018).","journal-title":"BMC Psychiatry"},{"key":"3800_CR54","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner, K. et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am. J. Psychiatry 168, 1266\u20131277 (2011).","journal-title":"Am. J. Psychiatry"},{"key":"3800_CR55","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","volume":"46","author":"T Kishimoto","year":"2016","unstructured":"Kishimoto, T. et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol. Med. 46, 1459\u20131472 (2016).","journal-title":"Psychol. Med."},{"key":"3800_CR56","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery, S. A. & Asberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382\u2013389 (1979).","journal-title":"Br. J. Psychiatry"},{"key":"3800_CR57","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush, A. J. et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 54, 573\u2013583 (2003).","journal-title":"Biol. Psychiatry"},{"key":"3800_CR58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jad.2020.12.185","volume":"282","author":"CD Moulton","year":"2021","unstructured":"Moulton, C. D. et al. The Maudsley 3-item Visual Analogue Scale (M3VAS): validation of a scale measuring core symptoms of depression. J. Affect. Disord. 282, 280\u2013283 (2021).","journal-title":"J. Affect. Disord."},{"key":"3800_CR59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1192\/bjp.167.1.99","volume":"167","author":"RP Snaith","year":"1995","unstructured":"Snaith, R. P. et al. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br. J. Psychiatry 167, 99\u2013103 (1995).","journal-title":"Br. J. Psychiatry"},{"key":"3800_CR60","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jrp.2005.11.001","volume":"40","author":"DE Gard","year":"2006","unstructured":"Gard, D. E., Gard, M. G., Kring, A. M. & John, O. P. Anticipatory and consummatory components of the experience of pleasure: a scale development study. J. Res. Personal. 40, 1086\u20131102 (2006).","journal-title":"J. Res. Personal."},{"key":"3800_CR61","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024465317902","volume":"11","author":"JD Bremner","year":"1998","unstructured":"Bremner, J. D. et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J. Trauma Stress 11, 125\u2013136 (1998).","journal-title":"J. Trauma Stress"},{"key":"3800_CR62","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2008.02.020","volume":"103","author":"OJ Mason","year":"2008","unstructured":"Mason, O. J., Morgan, C. J., Stefanovic, A. & Curran, H. V. The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophr. Res. 103, 138\u2013142 (2008).","journal-title":"Schizophr. Res."},{"key":"3800_CR63","doi-asserted-by":"crossref","first-page":"e4484","DOI":"10.1002\/nbm.4484","volume":"34","author":"A Lin","year":"2021","unstructured":"Lin, A. et al. Minimum Reporting Standards for in vivo Magnetic Resonance Spectroscopy (MRSinMRS): experts\u2019 consensus recommendations. NMR Biomed. 34, e4484 (2021).","journal-title":"NMR Biomed."},{"key":"3800_CR64","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/jmri.24478","volume":"40","author":"RAE Edden","year":"2014","unstructured":"Edden, R. A. E., Puts, N. A. J., Harris, A. D., Barker, P. B. & Evans, C. J. Gannet: a batch-processing tool for the quantitative analysis of gamma-aminobutyric acid\u2013edited MR spectroscopy spectra. J. Magn. Reson. Imaging 40, 1445\u20131452 (2014).","journal-title":"J. Magn. Reson. Imaging"},{"key":"3800_CR65","unstructured":"SPM. SPM12, version 7771 (Wellcome Centre for Human Neuroimaging, 2020)."},{"key":"3800_CR66","doi-asserted-by":"crossref","first-page":"200600","DOI":"10.1098\/rsos.200600","volume":"7","author":"V Truong","year":"2020","unstructured":"Truong, V. & Duncan, N. W. Suggestions for improving the visualization of magnetic resonance spectroscopy voxels and spectra. R. Soc. Open Sci. 7, 200600 (2020).","journal-title":"R. Soc. Open Sci."},{"key":"3800_CR67","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/mrm.25094","volume":"73","author":"J Near","year":"2015","unstructured":"Near, J. et al. Frequency and phase drift correction of magnetic resonance spectroscopy data by spectral registration in the time domain. Magn. Reson. Med. 73, 44\u201350 (2015).","journal-title":"Magn. Reson. Med."},{"key":"3800_CR68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/mrm.26091","volume":"77","author":"R Simpson","year":"2017","unstructured":"Simpson, R., Devenyi, G. A., Jezzard, P., Hennessy, T. J. & Near, J. Advanced processing and simulation of MRS data using the FID appliance (FID-A)\u2014an open source, MATLAB-based toolkit. Magn. Reson. Med. 77, 23\u201333 (2017).","journal-title":"Magn. Reson. Med."},{"key":"3800_CR69","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/nbm.698","volume":"14","author":"SW Provencher","year":"2001","unstructured":"Provencher, S. W. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 14, 260\u2013264 (2001).","journal-title":"NMR Biomed."},{"key":"3800_CR70","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1002\/mp.12375","volume":"44","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y., An, L. & Shen, J. Fast computation of full density matrix of multispin systems for spatially localized in vivo magnetic resonance spectroscopy. Med. Phys. 44, 4169\u20134178 (2017).","journal-title":"Med. Phys."},{"key":"3800_CR71","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/mrm.1910300604","volume":"30","author":"SW Provencher","year":"1993","unstructured":"Provencher, S. W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30, 672\u2013679 (1993).","journal-title":"Magn. Reson. Med."},{"key":"3800_CR72","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/(SICI)1097-0258(19960715)15:13<1421::AID-SIM266>3.0.CO;2-H","volume":"15","author":"KE James","year":"1996","unstructured":"James, K. E., Bloch, D. A., Lee, K. K., Kraemer, H. C. & Fuller, R. K. An index for assessing blindness in a multi-centre clinical trial: disulfiram for alcohol cessation \u2013 a VA cooperative study. Stat. Med. 15, 1421\u20131434 (1996).","journal-title":"Stat. Med."},{"key":"3800_CR73","unstructured":"Pinheiro, J. & Bates D. nlme: Linear and Nonlinear Mixed Effects Models. R version 3.1-157 https:\/\/cran.r-project.org\/web\/packages\/nlme\/nlme.pdf11\/27\/2024 (2022)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03800-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03800-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03800-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:03:39Z","timestamp":1788519819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03800-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":73,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3800"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03800-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.H.Y. is employed by Imperial College London, is an Honorary Consultant at South London and Maudsley NHS Foundation Trust (NHS UK), editor of the Journal of Psychopharmacology and deputy editor of BJPsych Open. A.H.Y. has been paid for lectures and is on advisory boards for the following companies with drugs used in affective and related disorders: Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema pharma, Compass, AstraZenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage and Neurocentrx. A.H.Y. is a principal investigator in the following: Restore-Life VNS registry study funded by LivaNova, ESKETINTRD3004: \u2018An open-label, long-term, safety and efficacy study of intranasal esketamine in treatment-resistant depression\u2019, \u2018The effects of psilocybin on cognitive function in healthy participants\u2019, \u2018The safety and efficacy of psilocybin in participants with treatment-resistant depression (P-TRD)\u2019, \u2018A double-blind, randomized, parallel-group study with quetiapine extended release as comparator to evaluate the efficacy and safety of seltorexant 20\u2009mg as adjunctive therapy to antidepressants in adult and elderly patients with major depressive disorder with insomnia symptoms who have responded inadequately to antidepressant therapy\u2019 (Janssen), \u2018An open-label, long-term, safety and efficacy study of aticaprant as adjunctive therapy in adult and elderly participants with major depressive disorder (MDD)\u2019 (Janssen), \u2018A randomized, double-blind, multicenter, parallel-group, placebo-controlled study to evaluate the efficacy, safety, and tolerability of aticaprant 10\u2009mg as adjunctive therapy in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia and inadequate response to current antidepressant therapy\u2019, \u2018A study of disease characteristics and real-life standard of care effectiveness in patients with major depressive disorder (MDD) with anhedonia and inadequate response to current antidepressant therapy including an SSRI or SNR\u2019 (Janssen) as well as UK Chief Investigator for Compass (COMP006 & COMP007 studies) and Novartis MDD study (MIJ821A12201). A.H.Y. has received grant funding (past and present) from: NIMH (USA), CIHR (Canada), NARSAD (USA), Stanley Medical Research Institute (USA), MRC (UK), Wellcome Trust (UK), Royal College of Physicians (Edinburgh, UK), BMA (UK), UBC-VGH Foundation (Canada), WEDC (Canada), CCS Depression Research Fund (Canada), MSFHR (Canada), NIHR (UK) and Janssen (UK) EU Horizon 2020. M.A.M. has current funding from Nxera, Takeda and Lundbeck and has acted as an advisor for Boehringer Ingelheim, Neurocentrx, Quolet Pharmaceuticals and Nxera. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}